Valerio Therapeutics
ALVIO
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.
Contact
49 Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
38
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,599.40 | 56.50 | 0.66% |
CAC 40 | 7,401.88 | 87.47 | -1.17% |
DAX 40 | 20,261.84 | 78.73 | -0.39% |
Dow JONES (US) | 42,345.12 | 183.24 | -0.43% |
FTSE 100 | 8,224.70 | 20.58 | -0.25% |
HKSE | 19,279.84 | 167.74 | -0.86% |
NASDAQ | 19,443.96 | 45.72 | -0.23% |
Nikkei 225 | 39,981.06 | 102.24 | -0.26% |
NZX 50 Index | 13,043.11 | 1.05 | 0.01% |
S&P 500 | 5,891.45 | 17.58 | -0.30% |
S&P/ASX 200 | 8,349.10 | 64.00 | 0.77% |
SSE Composite Index | 3,230.17 | 0.52 | 0.02% |